PMID: 20135894Feb 9, 2010Paper

The intersection of pharmacology, imaging, and genetics in the development of personalized medicine.

Dialogues in Clinical Neuroscience
Philip GerretsenBruce G Pollock

Abstract

We currently rely on large randomized controlled trials and meta-analyses to make clinical decisions; this places us at a risk of discarding subgroup or individually specific treatment options owing to their failure to prove efficacious across entire populations. There is a new era emerging in personalized medicine that will focus on individual differences that are not evident phenomenologically. Much research is directed towards identifying genes, endophenotypes, and biomarkers of disease that will facilitate diagnosis and predict treatment outcome. We are at the threshold of being able to predict treatment response, primarily through genetics and neuroimaging. In this review we discuss the most promising markers of treatment response and adverse effects emerging from the areas of pharmacogenetics and neuroimaging in depression and schizophrenia.

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Expert Opinion on Drug Metabolism & Toxicology
Jian-Ping Zhang, Anil K Malhotra
Expert Opinion on Drug Metabolism & Toxicology
Jian-Ping Zhang, Anil K Malhotra
Current Opinion in Anaesthesiology
Mindy CohenAlexander A Vinks
Harvard Review of Psychiatry
Katherine E BurdickAnil K Malhotra
The American Journal of Drug and Alcohol Abuse
Colin N HaileTherese A Kosten
© 2021 Meta ULC. All rights reserved